{
  "id": 7582299,
  "title": "Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS G12D mutations: a phase 1 trial",
  "url": "https://urgent.news/2026/09/15/oral-kras-g12d-inhibitor-gfh375-for-previously-treated-advanced-solid",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04559-4"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04559-4 In a phase 1 trial evaluating GFH375, an oral, dual on–off binding KRAS G12D inhibitor, in patients with KRASG12D-mutated solid tumors, there was one treatment-related death, while most treatment-related adverse events were low-grade, and encouraging response rates were observed in non-small cell lung cancer and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}